411242-06-3

Upstream product

• 411242-05-2 1(R)-(2-{5(R)-[4-bromo-2(R)-(tert-butyldiphenylsilanyloxy)but-3(Z)-enyl]-2,2,4(R)-trimethyl-[1,3]dioxolan-4(R)-yl}vinyl)but-3-enyl acrylate 
• 411242-15-4 1-{5(R)-[4-bromo-2(R)-(tert-butyldiphenylsilanyloxy)but-3(Z)-enyl]-2,2,4(R)-trimethyl-[1,3]dioxolan-4(R)-yl}hexa-1(E),5-dien-3(R)-ol 
• 411242-02-9 {5(R)-[4-bromo-2(R)-(tert-butyldiphenylsilanyloxy)but-3(Z)-enyl]-2,2,4(R)-trimethyl-[1,3]dioxolane-4(R)-yl}methanol 
• 411242-03-0 5(R)-[4-bromo-2(R)-(tert-butyldiphenylsilanyloxy)but-3(Z)-enyl]-2,2,4(S)-trimethyl-[1,3]dioxolane-4(S)-carbaldehyde 
• 411242-00-7 ethyl 5(R)-(tert-butyldiphenylsilanyloxy)-2-methylhept-2(E)-en-6-ynoate 
• 411241-99-1 (R)-tert-butyl(hex-5-en-1-yn-3-yloxy)diphenylsilane 
• 411242-11-0 3(R)-(tert-butyldiphenylsilanyloxy)pent-4-ynal 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 411242-16-5 6(R)-(2-{5(R)-[4-bromo-2(R)-(tert-butyldiphenylsilanyloxy)but-3(Z)-enyl]-2,2,4(R)-trimethyl-[1,3]dioxolan-4(R)-yl}-vinyl)-5,6-dihydropyran-2-one 
• 208336-98-5 5-hexen-1-yn-3(R)-ol 

Downstream Products

• 411242-08-5 6(R)-[6(R),13-bis(tert-butyldiphenylsilanyloxy)-3(R),4(R)-dihydroxy-3(R)-methyltrideca-1(E),7(Z),9(Z),11(E)-tetraenyl]-5,6-dihydropyran-2-one 
• 411242-09-6 6(R)-[3(R)-(tert-butyldimethylsilanyloxy)-6(R),13-bis-(tert-butyldiphenylsilanyloxy)-4(R)-hydroxy-3(R)-methyltrideca-1(E),7(Z),9(Z),11(E)-tetraenyl]-5,6-dihydro-pyran-2-one 
• 411242-10-9 1-[1(R)-(tert-butyldimethylsilanyloxy)-1(R)-methyl-3-(6-oxo-3,6-dihydro-2H-pyran-2(R)-yl)allyl]-3(R),10-bis(tert-butyldiphenylsilanyloxy)-deca-4(Z),6(Z),8(E)-trienyl bis[2-(trimethylsilanyl)ethyl] phosphate 

Relevant academic research and scientific papers

Asymmetric total synthesis of (+)-fostriecin

(equation presented) The title compound, a potent protein phosphatase inhibitor and anticancer agent, was prepared by an efficient, multiconvergent asymmetric synthesis. Key transformations include a ring forming olefin metathesis leading to the α,β-unsat